Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in EuropeReportar como inadecuado




Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Rheumatology and Therapy

, Volume 3, Issue 2, pp 245–256

First Online: 05 November 2016Received: 19 September 2016

Abstract

IntroductionBenepali was the first etanercept Enbrel biosimilar to be approved in the European Union. Both Benepali and Enbrel are available as autoinjector devices. In a recent survey, nurses from France, Germany, Italy, Spain, and the United Kingdom UK reported that their patients with rheumatoid arthritis RA would prefer the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. To determine whether patients’ perceptions were similar to those of the nurses, this survey evaluated patients’ perceptions and preferences of the Benepali autoinjector versus the Enbrel MYCLIC autoinjector in the same five European countries.

MethodsPatients with RA using the Enbrel MYCLIC autoinjector participated in a 25-min, face-to-face questionnaire-interview. Patients were also shown an instructional video and device-handling leaflet, received a live demonstration on the Benepali autoinjector, and had access to both Benepali and Enbrel MYCLIC training autoinjectors. Patients rated the importance of ten autoinjector attributes on a seven-point scale 1 = not important at all; 7 = extremely important and provided their autoinjector preferences based on specific attributes. Patients also gave their opinion on which autoinjector they would prefer to use for self-injection.

ResultsOverall, 220 patients participated in the survey France, n = 30; Germany, n = 65; Italy, n = 67; Spain, n = 12; UK, n = 46. ‘Easy to operate the self-injection’ was ranked as the most important attribute mean score of 6.8, followed by ‘easy to grip’ 6.5, and ‘intuitive-self-explaining usage’ 6.3. Patients preferred the Benepali autoinjector, with the attribute of ‘easier to operate’ being a strong differentiator compared to the Enbrel MYCLIC autoinjector. Most patients 74% reported that they would prefer to use the Benepali autoinjector over the Enbrel MYCLIC autoinjector. ‘Easy to operate the self-injection’ and ‘button-free autoinjector’ were key drivers when selecting an autoinjector.

ConclusionsPatients in Europe reported a preference for the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. This finding is consistent with results from a recently reported nurse survey.

Funding: Biogen.

KeywordsAutoinjector Benepali Biosimilar Enbrel Etanercept Patients Rheumatoid arthritis Survey Enhanced contentTo view enhanced content for this article go to http:-www.medengine.com-Redeem-8317F06012637BFB.

Electronic supplementary materialThe online version of this article doi:10.1007-s40744-016-0048-9 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Kunal Thakur - Anna Biberger - Alexandra Handrich - Mourad Farouk Rezk

Fuente: https://link.springer.com/







Documentos relacionados